Search Results - "Wung, Peter"

SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772) by Raghu, Ganesh, Richeldi, Luca, Crestani, Bruno, Wung, Peter, Bejuit, Raphael, Esperet, Corinne, Antoni, Christian, Soubrane, Christina

“…A phase 2b trial (NCT02345070) was conducted to evaluate the efficacy and safety of two dose levels/regimens of SAR156597 (a bispecific IgG4 antibody that…”
Get full text

Upadacitinib: Mechanism of action, clinical, and translational science by Mohamed, Mohamed‐Eslam F., Bhatnagar, Sumit, Parmentier, Julie M., Nakasato, Priscila, Wung, Peter

“…Upadacitinib is a selective Janus kinase (JAK) inhibitor which is approved by the US Food and Drug Administration, the European Medicines Agency, as well as…”
Get full text

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study by Baraliakos, Xenofon, van der Heijde, Désirée, Sieper, Joachim, Inman, Robert Davies, Kameda, Hideto, Maksymowych, Walter Peter, Lagunes-Galindo, Ivan, Bu, Xianwei, Wung, Peter, Kato, Koji, Shmagel, Anna, Deodhar, Atul

“…The efficacy and safety of upadacitinib in patients with ankylosing spondylitis (AS) and inadequate response/intolerance to biologic disease-modifying…”
Get full text

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study by Baraliakos, Xenofon, van der Heijde, Désirée, Sieper, Joachim, Inman, Robert D, Kameda, Hideto, Li, Yihan, Bu, Xianwei, Shmagel, Anna, Wung, Peter, Song, In-Ho, Deodhar, Atul

“…Background Upadacitinib, a Janus kinase inhibitor, has demonstrated efficacy and an acceptable safety profile in patients with ankylosing spondylitis (AS) in…”
Get full text

Modeling and Effects of In Situ Magnetization of Isotropic Ferrite Magnet Motors by Min-Fu Hsieh, Dorrell, David G., Ching-Kuo Lin, Po-Ting Chen, Wung, Peter Y. P.

“…This paper outlines a method using finite-element analysis (FEA) to model the magnetization process of a small brushless surface-magnet three-phase motor with…”
Get full text

Population pharmacokinetics and exposure‐response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis by Bhatnagar, Sumit, Eckert, Doerthe, Stodtmann, Sven, Song, In‐Ho, Wung, Peter, Liu, Wei, Mohamed, Mohamed‐Eslam F.

“…Upadacitinib is an orally administered, selective, Janus kinase inhibitor that is approved for several auto‐immune conditions, such as axial spondyloarthritis,…”
Get full text

Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study by McInnes, Iain B., Kato, Koji, Magrey, Marina, Merola, Joseph F., Kishimoto, Mitsumasa, Haaland, Derek, Chen, Liang, Duan, Yuanyuan, Liu, Jianzhong, Lippe, Ralph, Wung, Peter

“…Introduction Efficacy and safety of the Janus kinase (JAK) inhibitor upadacitinib (UPA) was evaluated in patients with psoriatic arthritis (PsA) through week…”
Get full text

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension by van der Heijde, Désirée, Deodhar, Atul, Maksymowych, Walter P, Sieper, Joachim, Van den Bosch, Filip, Kim, Tae-Hwan, Kishimoto, Mitsumasa, Östör, Andrew J, Combe, Bernard, Sui, Yunxia, Duan, Yuanyuan, Wung, Peter K, Song, In-Ho

“…IntroductionLong-term safety and efficacy of upadacitinib in patients with active ankylosing spondylitis (AS) has not been previously reported.MethodsIn…”
Get full text

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials by Burmester, Gerd R., Stigler, Jayne, Rubbert-Roth, Andrea, Tanaka, Yoshiya, Azevedo, Valderilio F., Coombs, Derek, Lagunes, Ivan, Lippe, Ralph, Wung, Peter, Gensler, Lianne S.

“…Introduction This integrated analysis of the phase 2/3 and phase 3 SELECT trials describes the safety profile of upadacitinib, an oral Janus kinase inhibitor,…”
Get full text

Upadacitinib in Active Non‐radiographic Axial Spondyloarthritis: 1‐Year Data From a Double‐Blind, Randomized, Placebo‐Controlled, Phase 3 Trial by Van den Bosch, Filip, Deodhar, Atul, Poddubnyy, Denis, Maksymowych, Walter P., Heijde, Désirée, Kim, Tae‐Hwan, Kishimoto, Mitsumasa, Baraliakos, Xenofon, Li, Yihan, D'Silva, Kristin, Wung, Peter, Song, In‐Ho

“…Objective Upadacitinib improved the signs and symptoms of non‐radiographic axial spondyloarthritis (nr‐axSpA) versus placebo over 14 weeks in the primary…”
Get full text

Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2 by Kiltz, Uta, Kishimoto, Mitsumasa, Walsh, Jessica A., Sampaio-Barros, Percival, Mittal, Manish, Saffore, Christopher D., Wung, Peter, Ganz, Fabiana, Biljan, Ana, Poddubnyy, Denis

“…Introduction To evaluate the effect of upadacitinib vs. placebo on health-related quality of life (HRQoL) and work productivity in patients with active…”
Get full text

Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon by Fava, Andrea, Wung, Peter K., Wigley, Fredrick M., Hummers, Laura K., Daya, Natalie R., Ghazarian, Sharon R., Boin, Francesco

“…Objective The RhoA/Rho kinase pathway plays a pivotal role in cold‐induced vasoconstriction, vascular smooth muscle cells function, and vascular homeostasis…”
Get full text

Herpes zoster in immunocompromised patients: incidence, timing, and risk factors by Wung, Peter K, Holbrook, Janet T, Hoffman, Gary S, Tibbs, Andrea K, Specks, Ulrich, Min, Y-I, Merkel, Peter A, Spiera, Robert, Davis, John C, St Clair, E William, McCune, Joseph, Ytterberg, Steven R, Allen, Nancy B, Stone, John H

“…To evaluate the risk factors for herpes zoster as well as the incidence and timing of this complication in patients who were treated with immunosuppression…”
Get more information

“Still” Ill? by Wung, Peter K., MD, Pipeling, Matthew R., MD, Wigley, Fredrick M., MD

“…Wung et al describe the case of a 59-year-old Caucasian man with daily high fevers, drenching night sweats, malaise, and a profound 45-lb weight loss. He also…”
Get full text

Therapeutics of Wegener's granulomatosis by Stone, John H, Wung, Peter K

“…The treatment of Wegener's granulomatosis, one of the most common forms of systemic vasculitis, has changed substantially over the past two decades. The…”
Get full text

Persistent positron emission tomography-positive liver lesions after successful chemotherapy in mediastinal seminoma by HOLDHOFF, Matthias, WUNG, Peter K, PETRONIS, John D, COUZI, Rima

Get full text

An atypical complication of atypical pneumonia by Antonarakis, Emmanuel S, Wung, Peter K, Durand, Daniel J, Leyngold, Ilya, Meyerson, David A

Get more information

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis by Allanore, Yannick, Wung, Peter, Soubrane, Christina, Esperet, Corinne, Marrache, Frederic, Bejuit, Raphael, Lahmar, Amel, Khanna, Dinesh, Denton, Christopher P

“…Recent advances in systemic sclerosis (SSc) show that it involves a T-helper type-2-oriented immune response with interleukin (IL)-4 and IL-13. Romilkimab is…”
Get more information

Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis by Wung, Peter K., Anderson, Troy, Fontaine, Kevin R., Hoffman, Gary S., Specks, Ulrich, Merkel, Peter A., Spiera, Robert, Davis, John C., St.Clair, E. William, McCune, W. Joseph, Stone, John H.

“…Objective Weight gain is a side effect of glucocorticoid (GC) use, but the natural history and health implications of changes in weight that occur during the…”
Get full text

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial by Deodhar, Atul, Van den Bosch, Filip, Poddubnyy, Denis, Maksymowych, Walter P, van der Heijde, Désirée, Kim, Tae-Hwan, Kishimoto, Mitsumasa, Blanco, Ricardo, Duan, Yuanyuan, Li, Yihan, Pangan, Aileen L, Wung, Peter, Song, In-Ho

“…Summary Background Upadacitinib, a Janus kinase inhibitor, has been shown to be effective in patients with ankylosing spondylitis. We aimed to assess the…”
Get full text